• Home

  • All Infos

  • Videos Gallery

  • (NEW !) Startups Ecosystems

    • News of Startups Ecosystems
    • (-)Techs Portraits
  • Advertising

  • Plus

    Use tab to navigate through the menu items.
    • LinkedIn Social Icône
    ScreenHunter_03 Jan. 15 15.50.jpg
    ScreenHunter_03 Jan. 15 15.50.jpg

    swissnews.info keeps you posted!

    banner-swissnews-300x250.gif
    CT immagini2.jpg
    banner web.png
    To see this working, head to your live site.
    • Categories
    • All Posts
    • My Posts
    Editions Mancassola
    Oct 27, 2021
    Edited: Oct 27, 2021

    SUN BIOSCIENCE RECEIVES A TECH GROWTH LOAN OF 500,000CHF FOR ITS ORGANOID PRODUCTION TECHNOLOGY

    in Health-/Med-/BioTech

    Founded in 2016, SUN bioscience has developed a solution for the industrial and automated production of organoids. The Tech Growth loan granted by the Foundation for Technological Innovation (FIT) will allow the start-up to further scale and industrialize its product and hire additional staff.


    In pharmaceutical research scientists culture cells and observe their interactions. One way of doing this is by using two-dimensional systems, known as static systems. With the use of two-dimensional plastic dishes, the cells only behave in a 2D field, which makes it easier to control the environment but does not reflect the reality of human cell interactions. 3D cell culture systems have been developed to recreate the environment present in the human body and thereby provide a framework for cells to form structures called spheroids in which they can interact with each other. Various media exist for 3D culture such as sponges, gels or plastic bases, however, all of these systems fail to provide high throughput and scalability.


    In order to guarantee the integrity of the cultures, SUN bioscience has relied on organoids to facilitate 3D cultures. Organoids are three-dimensional multicellular structures that reproduce in vitro the micro-anatomy of an organ, i.e. a mini-organ. Cultivated from human derived stem cells, they have enormous potential for studying interactions with pathogens or for deciphering physiological processes. The start-up is the first to produce organoids industrially and automatically on 96-well culture plates. Its device can be inserted directly in standard workflow processes of pharmaceutical companies. In addition, the composition of the hydrogel in which the organoids will grow, the culture method and the culture plates are new and entirely developed by the start-up.


    Read the whole article




    0 comments
    0
    Comments

    Share Your ThoughtsSign up to leave a comment.

    0 comments
    Editions Mancassola
    Mar 18

    Un nouveau pas vers la durabilité dans le domaine du luxe

    Editions Mancassola
    Feb 02

    E4S and OriginAll call on brands to participate to world's first index on the efficiency of luxury industry’s traceability technologies

    Editions Mancassola
    Jan 11

    Partisia Blockchain Partners with OriginAll to Tackle Counterfeit Medicine Fraud in African Countries

    Editions Mancassola
    Nov 15, 2021

    Swiss fintech Amnis receives EEA payment institution license and expands to Europe

    Editions Mancassola
    Oct 28, 2021

    Fake Goods, Real News - How criminal organizations are plundering half a trillion dollars from Africa through counterfeiting?

    Editions Mancassola
    Oct 27, 2021

    Proptech suisse : lancement d’Immowise, toute première solution numérique pour accompagner les assemblées générales de copropriété